Coegin Pharma AB (NGM:COEGIN)
Sweden · Delayed Price · Currency is SEK 3.000
+0.080 (2.74%)
At close: Sep 8, 2026
Coegin Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.48 | 7.92 | 19.68 | 5.55 | 3.82 | 25.66 |
Cash & Short-Term Investments | 2.48 | 7.92 | 19.68 | 5.55 | 3.82 | 25.66 |
Cash Growth | -79.89% | -59.74% | 254.70% | 45.39% | -85.13% | 54.12% |
Accounts Receivable | 0.08 | 0.07 | - | - | - | - |
Other Receivables | 0.69 | 0.51 | 0.99 | 0.64 | 3.13 | 4.64 |
Receivables | 0.77 | 0.58 | 0.99 | 0.64 | 3.13 | 4.64 |
Prepaid Expenses | 0.24 | 0.27 | 0.17 | 0.02 | 0.02 | 0.03 |
Other Current Assets | 0.25 | 1.23 | -0 | - | - | - |
Total Current Assets | 5.66 | 10 | 20.84 | 6.21 | 6.97 | 30.33 |
Property, Plant & Equipment | 0.57 | 0.11 | 0.15 | 0.3 | 0.49 | 0 |
Other Intangible Assets | 1.74 | 3.18 | 6.05 | 8.92 | 11.79 | - |
Other Long-Term Assets | -0 | 0.06 | - | - | 10 | - |
Total Assets | 8.1 | 13.34 | 27.04 | 15.43 | 29.25 | 30.34 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.35 | 0.64 | 0.98 | 1.79 | 2 | 9.73 |
Accrued Expenses | 1.38 | 2.59 | 0.66 | 2.66 | 1.71 | 0.22 |
Current Income Taxes Payable | 0.02 | - | - | - | 0.18 | - |
Other Current Liabilities | 0.29 | 5.37 | 0.15 | 4.24 | 4.34 | 0.31 |
Total Current Liabilities | 2.04 | 8.6 | 1.78 | 8.68 | 8.23 | 10.26 |
Total Liabilities | 2.04 | 8.6 | 1.78 | 8.68 | 8.23 | 10.26 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 14.3 | 12.44 | 12.44 | 4.7 | 35.33 | 27.57 |
Additional Paid-In Capital | 146.4 | 136.2 | 136.2 | 101.6 | 94.76 | 66.38 |
Retained Earnings | - | - | - | - | - | -75.07 |
Comprehensive Income & Other | -154.65 | -143.9 | -123.38 | -99.54 | -109.08 | 1.2 |
Shareholders' Equity | 6.05 | 4.74 | 25.26 | 6.75 | 21.01 | 20.07 |
Total Liabilities & Equity | 8.1 | 13.34 | 27.04 | 15.43 | 29.25 | 30.34 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 2.48 | 7.92 | 19.68 | 5.55 | 3.82 | 25.66 |
Net Cash Growth | -79.89% | -59.74% | 254.70% | 45.39% | -85.13% | 54.12% |
Net Cash Per Share | 0.10 | 0.32 | 1.04 | 0.60 | 0.56 | 4.32 |
Filing Date Shares Outstanding | 28.59 | 24.88 | 24.88 | 9.39 | 6.94 | 6.94 |
Total Common Shares Outstanding | 28.59 | 24.88 | 24.88 | 9.39 | 6.94 | 6.94 |
Working Capital | 3.61 | 1.4 | 19.06 | -2.47 | -1.26 | 20.07 |
Book Value Per Share | 0.21 | 0.19 | 1.02 | 0.72 | 3.03 | 2.89 |
Tangible Book Value | 4.31 | 1.56 | 19.21 | -2.17 | 9.22 | 20.07 |
Tangible Book Value Per Share | 0.15 | 0.06 | 0.77 | -0.23 | 1.33 | 2.89 |
Machinery | - | 0.72 | 0.63 | 0.64 | 0.68 | 0.15 |